# Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus

> **NCT00611663** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 47 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **BIOLOGICAL:** Prevenar® and Pneumo23®
- **BIOLOGICAL:** Placebo, Pneumo23®

## Key facts

- **NCT ID:** NCT00611663
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2014-12
- **Final completion:** 2016-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00611663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00611663, "Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00611663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*